<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561338</url>
  </required_header>
  <id_info>
    <org_study_id>HMM0201</org_study_id>
    <nct_id>NCT02561338</nct_id>
  </id_info>
  <brief_title>A Multi-center 12-week Study of HMS5552 in T2DM</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, 12-week Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Population PK of HMS5552 in Type 2 Diabetic Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Medicine Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hua Medicine Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability, efficacy and population PK of HMS5552 in type
      2 diabetic adult subjects,there will be 5 groups ,4 groups will receive HMS5552,while 1 will
      receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucokinase (GK, also called hexokinase IV or D) can phosphosphorylate glucose to
      glucose-6-phosphate (G-6-P) in pancreatic β-cells and liver cells, which represents the first
      step of glucose metabolism. GK also acts as a glucose sensor and exerts a key role in
      maintaining glucose homeostasis. HMS5552 is a 4th-generation GK agonist or activator (GKA),
      which was originally licensed from Roche and subsequently developed by Hua Medicine. HMS5552
      has been shown to activate GK in pancreatic beta cells, liver and intestinal epithelial
      cells. It regulates systemic blood glucose through a variety of mechanisms including directly
      enhancing insulin release (pancreas), inhibiting production of endogenous glucose (liver) and
      by indirectly promoting GLP-1 release (enteroendocrine L-cells).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in HbA1c</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events relevant to GK activation or of other interest: hypoglycemia, hepatic adverse events/or abnormal liver tests, elevation of lipid parameters, etc. safety</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in FPG</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in PPG</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in MMTT (mixed meal tolerance test) β-cell function index</measure>
    <time_frame>week 4, week 12 and follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BID oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BID oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QD oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QD oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, BID/QD oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <description>50mgBID/75mgBID/75mgQD/100mgQD</description>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <other_name>GKA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo BID/QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male &amp; female, 40~75 years old

          2. T2DM patients，anti-hyperglycemic drug-naïve and on diet &amp; exercise for at least 3
             months, or with glucose controlled by Metformin or α-glucosidase inhibitor alone

          3. HbA1c 7.5~10.5% at screening and pre-randomization

          4. Fasting plasma glucose (FPG)7.0~11.1mM (local lab) at screening, and 7.0~13.3mM
             (central lab) at pre-randomization

          5. BMI: 19~30kg/m2 &amp; TG&lt;5.5mM

        Exclusion Criteria:

          1. T1D，secondary DM, pre-DM

          2. kidney diseases or eGFR MDRD&lt;60ml/min/1.73m2

          3. unstable CVDs，

          4. liver diseases，

          5. mental or CNS diseases，
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalong Zhu, MD，PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GKA,T2DM,HMS5552</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>February 5, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>February 6, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>February 7, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

